Guo Yaling, Yu Hongjun, Deng Li, Chen Jingli
Department of Endocrinology and Diabetes, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine Cangzhou, Hebei, China.
Am J Transl Res. 2025 Jul 15;17(7):5163-5172. doi: 10.62347/LABZ1345. eCollection 2025.
This study assesses the efficacy of Jie Yu Xiao Yin (JYXY), a Traditional Chinese Medicine (TCM) formulation, on Hashimoto's Thyroiditis (HT).
Ninety HT patients (2020-2022) were randomized to JYXY + levothyroxine (n = 45) or levothyroxine alone (n = 45) for 12 weeks. JYXY (300 mL/day) and levothyroxine (12.5-25 µg/day) were provided. Thyroid hormones (thyroid stimulating hormone (TSH), free thyroxine (FT4), free triiodothyronine (FT3)), antibodies (thyroid peroxidase (TPOAb), thyroglobulin (TGAb)), interleukin (IL 6, 10, 12, 17), transforming growth factor-beta (TGF-β), and TCM scores were measured at baseline and in weeks 4, 8, and 12. The final study included 86 patients (44 treatment and 42 control).
Baseline parameters were comparable (P > 0.05). At week 12, the treatment group showed greater reductions in TSH (3.06 ± 0.59 vs. 4.89 ± 0.71; P < 0.001), TPOAb (165.37 ± 8.55 vs. 199.28 ± 13.81 IU/mL; P < 0.001), and TGAb (159.77 ± 9.37 vs. 178.26 ± 13.04 IU/mL; P < 0.001). Pro-inflammatory cytokines decreased significantly in the JYXY group: IL-6 (16.02 ± 6.34 vs. 19.84 ± 5.21), IL-17 (21.07 ± 8.95 vs. 30.45 ± 10.12), and TGF-β (18.91 ± 6.12 vs. 22.34 ± 5.67) (all P < 0.001). IL-10 and IL-12 remained unchanged (P > 0.05). TCM scores improved markedly (3.70 ± 0.90 vs. 7.42 ± 4.38; P < 0.001), with higher clinical efficacy (87.63% vs. 69.05%; P < 0.001).
JYXY coupled with levothyroxine improves thyroid function, decreases autoantibodies and pro-inflammatory cytokines (IL-6, IL-17, TGF-β), and alleviates symptoms in HT patients, outperforming levothyroxine alone.
本研究评估中药制剂解郁消瘿（JYXY）对桥本甲状腺炎（HT）的疗效。
90例HT患者（2020 - 2022年）被随机分为JYXY联合左甲状腺素组（n = 45）或单纯左甲状腺素组（n = 45），治疗12周。给予JYXY（300毫升/天）和左甲状腺素（12.5 - 25微克/天）。在基线以及第4、8和12周测量甲状腺激素（促甲状腺激素（TSH）、游离甲状腺素（FT4）、游离三碘甲状腺原氨酸（FT3））、抗体（甲状腺过氧化物酶（TPOAb）、甲状腺球蛋白（TGAb））、白细胞介素（IL - 6、10、12、17）、转化生长因子 - β（TGF - β）以及中医评分。最终研究纳入86例患者（44例治疗组和42例对照组）。
基线参数具有可比性（P > 0.05）。在第12周时，治疗组的TSH（3.06 ± 0.59对4.89 ± 0.71；P < 0.001）、TPOAb（165.37 ± 8.55对199.28 ± 13.81 IU/mL；P < 0.001）和TGAb（159.77 ± 9.37对178.26 ± 13.04 IU/mL；P < 0.001）下降幅度更大。JYXY组促炎细胞因子显著降低：IL - 6（16.02 ± 6.34对19.84 ± 5.21）、IL - 17（21.07 ± 8.95对30.45 ± 10.12）和TGF - β（18.91 ± 6.12对22.34 ± 5.67）（均P < 0.001）。IL - 10和IL - 12保持不变（P > 0.05）。中医评分显著改善（3.70 ± 0.90对7.42 ± 4.38；P < 0.001），临床疗效更高（87.63%对69.05%；P < 0.001）。
JYXY联合左甲状腺素可改善HT患者的甲状腺功能，降低自身抗体和促炎细胞因子（IL - 6、IL - 17、TGF - β），并缓解症状，效果优于单纯使用左甲状腺素。
